April 16, 2020

Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test

PUBLICATION: 
Translational Oncology Volume 13, Issue 4, April 2020, 100756

AUTHORS: 
Lorenza Mittempergher, Leonie JMJ Delahaye, Anke T Witteveen, Mireille HJ Snel, Sammy Mee, Bob Y Chan, Christa Dreezen, Naomi Besseling, Ernest JT Luiten, Annuska M Glas

SUMMARY: 
The analytical performance of a multi-gene diagnostic signature depends on many parameters, including precision, repeatability, reproducibility and intra-tumor heterogeneity. Here we study the analytical performance of the BluePrint 80-gene breast cancer molecular subtyping test through determination of these performance characteristics. BluePrint measures the expression of 80 genes that assess functional pathways which determine the intrinsic breast cancer mo- lecular subtypes (i.e. Luminal-type, HER2-type, Basal-type). Knowing a tumor’s dominant functional pathway can help allocate effective treatment to appropriate patients

Read more: Long Term Analytical Validation Study Further Confirms BluePrint as a Reliable Genomic Profiling Assay for Early Stage Breast Cancer Patients